⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3342266 | 0.88 | — | — | |
| SCHEMBL286213 | 0.84 | HSD17B10 (0.30) | — | |
| SCHEMBL2010687 | 0.78 | — | — | |
| SCHEMBL22436717 | 0.75 | — | — | |
| SCHEMBL17850612 | 0.72 | — | — | |
| SCHEMBL22319209 | 0.72 | — | — | |
| SCHEMBL16708768 | 0.70 | — | — | |
| SCHEMBL19448472 | 0.70 | — | — | |
| SCHEMBL24357923 | 0.69 | DPP4 (0.30) | — | |
| SCHEMBL24372277 | 0.69 | DPP4 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3723754-B1 | IMIDAZO [1,2-C] QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | MERCK SHARP & DOHME LLC (US) | 2026-05-13 | — | — | EP | claimed |
| US-20200216419-A1 | BENZIMIDAZOLES FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES | CAPELLA THERAPEUTICS, INC. | 2020-07-09 | — | — | US | claimed |
| US-10590108-B2 | Benzimidazoles for use in the treatment of cancer and inflammatory diseases | CAPELLA THERAPEUTICS, INC. (US) | 2020-03-17 | — | — | US | claimed |
| US-20180273511-A1 | BENZIMIDAZOLES FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES | CAPELLA THERAPEUTICS, INC. | 2018-09-27 | — | — | US | claimed |
| US-20170304292-A1 | Tetrahydroisoquinoline Derivatives | UCB BIOPHARMA SPRL (BE) | 2017-10-26 | — | — | US | claimed |
| EP-3204359-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES | UCB Biopharma SPRL (BE) | 2017-08-16 | — | — | EP | claimed |
| WO-2017053537-A1 | BENZIMIDAZOLES FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES | CAPELLA THERAPEUTICS, INC. (US) | 2017-03-30 | — | — | WO | claimed |
| WO-2016055479-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES | UCB BIOPHARMA SPRL (BE) | 2016-04-14 | — | — | WO | claimed |
| US-8106046-B2 | Cyclopentathiophene modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-01-31 | — | — | US | claimed |
| US-8008287-B2 | Use treating HIV and AIDS; tricyclic compounds such as those based on 5-sulfonamido-9-hydroxy-6,8-dihydrdo-7H-pyrrolo[3,4-g]quinoline-8-one | GILEAD SCIENCES, INC. (US) | 2011-08-30 | — | — | US | claimed |
| WO-2011073277-A1 | PIPERIDINE ARYL SULFONAMIDE DERIVATIVES AS Kv1.3 MODULATORS | EVOTEC AG (DE) | 2011-06-23 | — | — | WO | claimed |
| WO-2011073273-A1 | BENZOXAZINE ARYL SULFONAMIDE DERIVATIVES AS KV1.3 MODULATORS | EVOTEC AG (DE) | 2011-06-23 | — | — | WO | claimed |
| EP-2334671-A1 | CYCLOPENTATHIOPHENE MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-KAPPA B ACTIVITY AND USE THEREOF | Bristol-Myers Squibb Company (US) | 2011-06-22 | — | — | EP | claimed |
| US-20110105495-A1 | CYCLOPENTATHIOPHENE MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2011-05-05 | — | — | US | claimed |
| WO-2009158380-A1 | CYCLOPENTATHIOPHENE MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-KAPPA B ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-30 | — | — | WO | claimed |
| US-20090306054-A1 | INTEGRASE INHIBITORS | GILEAD SCIENCES ,INC. (US) | 2009-12-10 | — | — | US | claimed |
| EP-2066670-A2 | INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2009-06-10 | — | — | EP | claimed |
| US-20080058315-A1 | Integrase inhibitors | GILEAD SCIENCES, INC. | 2008-03-06 | — | — | US | claimed |
| WO-2007136714-A2 | INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2007-11-29 | — | — | WO | claimed |
| CN-115135659-B | Morpholine derivative, and preparation method and application thereof | 深圳微芯生物科技股份有限公司 | 2024-03-12 | — | — | CN | disclosed |
| US-20230271938-A1 | BENZIMIDAZOLES FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES | CAPELLA THERAPEUTICS, INC. | 2023-08-31 | — | — | US | disclosed |
| US-20230071483-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2023-03-09 | — | — | US | disclosed |
| CN-115135659-A | Morpholine derivatives and preparation method and application thereof | 深圳微芯生物科技股份有限公司 | 2022-09-30 | — | — | CN | disclosed |
| WO-2022152229-A1 | CLASS OF MORPHOLINE DERIVATIVES, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 深圳微芯生物科技股份有限公司 | 2022-07-21 | — | — | WO | disclosed |
| EP-2714703-B1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | NEWGEN THERAPEUTICS INC (US) | 2021-03-10 | — | — | EP | disclosed |
| US-20200216419-A1 | BENZIMIDAZOLES FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES | CAPELLA THERAPEUTICS, INC. | 2020-07-09 | — | — | US | disclosed |
| EP-3204359-B1 | TETRAHYDROISOQUINOLINE DERIVATIVES | UCB Biopharma SRL (BE) | 2020-07-01 | — | — | EP | disclosed |
| US-10590108-B2 | Benzimidazoles for use in the treatment of cancer and inflammatory diseases | CAPELLA THERAPEUTICS, INC. (US) | 2020-03-17 | — | — | US | disclosed |
| US-10590108-B2 | Benzimidazoles for use in the treatment of cancer and inflammatory diseases | CAPELLA THERAPEUTICS, INC. (US) | 2020-03-17 | — | — | US | disclosed |
| US-10105359-B2 | Tetrahydroisoquinoline derivatives | UCB BIOPHARMA SPRL (BE) | 2018-10-23 | — | — | US | disclosed |
| US-20180273511-A1 | BENZIMIDAZOLES FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES | CAPELLA THERAPEUTICS, INC. | 2018-09-27 | — | — | US | disclosed |
| CN-107629059-A | It can be used as the compound of ATR kinase inhibitors | 沃泰克斯药物股份有限公司 | 2018-01-26 | — | — | CN | disclosed |
| CN-107501275-A | It can be used as the compound of ATR kinase inhibitors | 沃泰克斯药物股份有限公司 | 2017-12-22 | — | — | CN | disclosed |
| CN-107501274-A | It can be used as the compound of ATR kinase inhibitors | 沃泰克斯药物股份有限公司 | 2017-12-22 | — | — | CN | disclosed |
| US-20170304292-A1 | Tetrahydroisoquinoline Derivatives | UCB BIOPHARMA SPRL (BE) | 2017-10-26 | — | — | US | disclosed |
| CN-104903325-B | Compounds useful as inhibitors of ATR kinase | 沃泰克斯药物股份有限公司 | 2017-10-20 | — | — | CN | disclosed |
| EP-3204359-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES | UCB Biopharma SPRL (BE) | 2017-08-16 | — | — | EP | disclosed |
| CN-106817900-A | Novel naphthyridines and isoquinolin and its purposes as CDK8/19 inhibitor | 默克专利有限公司 | 2017-06-09 | — | — | CN | disclosed |
| US-9643957-B2 | Heterocyclic compounds having cholesterol 24-hydroxylase activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-05-09 | — | — | US | disclosed |
| WO-2017053537-A1 | BENZIMIDAZOLES FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES | CAPELLA THERAPEUTICS, INC. (US) | 2017-03-30 | — | — | WO | disclosed |
| US-9593113-B2 | Imide and acylurea derivatives as modulators of the glucocorticoid receptor | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-14 | — | — | US | disclosed |
| US-20170057984-A1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | NEWGEN THERAPEUTICS INC (US) | 2017-03-02 | — | — | US | disclosed |
| WO-2017017630-A1 | NOVEL BETULINIC SUBSTITUTED AMIDE DERIVATIVES AS HIV INHIBITORS | HETERO RESEARCH FOUNDATION (IN) | 2017-02-02 | — | — | WO | disclosed |
| WO-2016055479-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES | UCB BIOPHARMA SPRL (BE) | 2016-04-14 | — | — | WO | disclosed |
| US-20160016951-A1 | NOVEL NAPHTHYRIDINES AND ISOQUINOLINES AND THEIR USE AS CDK8/19 INHIBITORS | MERCK PATENT GMBH (DE) | 2016-01-21 | — | — | US | disclosed |
| US-20150315209-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-11-05 | — | — | US | disclosed |
| WO-2014151729-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | IRM LLC (BM) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014151784-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | IRM LLC (BM) | 2014-09-25 | — | — | WO | disclosed |
| US-8106046-B2 | Cyclopentathiophene modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-01-31 | — | — | US | disclosed |
| US-8008287-B2 | Use treating HIV and AIDS; tricyclic compounds such as those based on 5-sulfonamido-9-hydroxy-6,8-dihydrdo-7H-pyrrolo[3,4-g]quinoline-8-one | GILEAD SCIENCES, INC. (US) | 2011-08-30 | — | — | US | disclosed |
| WO-2011073277-A1 | PIPERIDINE ARYL SULFONAMIDE DERIVATIVES AS Kv1.3 MODULATORS | EVOTEC AG (DE) | 2011-06-23 | — | — | WO | disclosed |
| WO-2011073273-A1 | BENZOXAZINE ARYL SULFONAMIDE DERIVATIVES AS KV1.3 MODULATORS | EVOTEC AG (DE) | 2011-06-23 | — | — | WO | disclosed |
| EP-2334671-A1 | CYCLOPENTATHIOPHENE MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-KAPPA B ACTIVITY AND USE THEREOF | Bristol-Myers Squibb Company (US) | 2011-06-22 | — | — | EP | disclosed |
| US-20110105495-A1 | CYCLOPENTATHIOPHENE MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2011-05-05 | — | — | US | disclosed |
| US-20100305116-A1 | Compounds Comprising a Cyclobutoxy Group | UCB PHARMA, S.A. (BE) | 2010-12-02 | — | — | US | disclosed |
| EP-2146980-A2 | HISTAMINE H3 RECEPTOR LIGANDS COMPRISING A CYCLOBUTOXY GROUP | UCB Pharma S.A. (BE) | 2010-01-27 | — | — | EP | disclosed |
| WO-2009158380-A1 | CYCLOPENTATHIOPHENE MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-KAPPA B ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-30 | — | — | WO | disclosed |
| US-20090306054-A1 | INTEGRASE INHIBITORS | GILEAD SCIENCES ,INC. (US) | 2009-12-10 | — | — | US | disclosed |
| EP-2066670-A2 | INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2009-06-10 | — | — | EP | disclosed |
| US-7465732-B2 | (2S,4S)-4-(piperazin-1-yl)pyrrolidine-2-methanone derivatives | PFIZER INC (US) | 2008-12-16 | — | — | US | disclosed |
| WO-2008128919-A2 | HISTAMINE H3 RECEPTOR LIGANDS COMPRISING A CYCLOBUTOXY GROUP | UCB PHARMA S.A. (BE) | 2008-10-30 | — | — | WO | disclosed |
| US-20080058315-A1 | Integrase inhibitors | GILEAD SCIENCES, INC. | 2008-03-06 | — | — | US | disclosed |
| WO-2007136714-A2 | INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2007-11-29 | — | — | WO | disclosed |
| US-7291618-B2 | Therapeutic compounds | PFIZER INC (US) | 2007-11-06 | — | — | US | disclosed |
| US-20070161664-A1 | THERAPEUTIC COMPOUNDS | PFIZER INC | 2007-07-12 | — | — | US | disclosed |
| US-20070099897-A1 | Therapeutic compounds | PFIZER INC | 2007-05-03 | — | — | US | disclosed |
| US-20060079498-A1 | Therapeutic compounds | PFIZER INC | 2006-04-13 | — | — | US | disclosed |
| US-20050256310-A1 | Therapeutic compounds | PFIZER INC | 2005-11-17 | — | — | US | disclosed |
| US-20050256310-A1 | Therapeutic compounds | PFIZER INC | 2005-11-17 | — | — | US | disclosed |